Salt

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart muscle digestion

Research Overview

Across the provided abstracts, salt research is most developed in three intersecting areas: (1) population and clinical cardiovascular outcomes linked to excess sodium intake (especially hypertension and downstream cardiovascular morbidity/mortality), (2) mechanistic studies in animal and cellular models describing how high salt perturbs organ systems (kidney, vasculature, brain, immune system) and promotes pathological remodeling (for example, cardiomyocyte metabolic reprogramming and hypertrophy), and (3) intervention and implementation research focused on reducing dietary sodium exposure, including reformulation of processed foods (notably meat products) and the use of potassium-containing salt substitutes. A smaller but notable set of studies addresses “salt” in other technical contexts—such as pharmaceutical salt forms that alter drug properties—and traditional processing practices (for example, salt-processing of herbal materials) that may change chemical composition and biological activity, though these are distinct from dietary sodium questions.

The strongest evidence supports a causal link between high salt intake and elevated blood pressure, with major public-health impact attributed to excess intake driven largely by “hidden” salt in processed foods. Among interventions, the most compelling evidence in these abstracts comes from a large cluster-randomized trial in older adults showing that a salt substitute (partial NaCl replacement with KCl) reduced systolic blood pressure and cardiovascular events, whereas restricting salt supply alone did not improve outcomes in that setting. Mechanistic evidence is also relatively strong (though largely preclinical) that high salt can drive cardiac hypertrophy via mitochondrial/metabolic pathways (for example, SIRT3 repression in salt-sensitive models) and that targeted therapies (for example, SGLT2 inhibition in animal models) can mitigate these effects; however, translation to humans remains to be established. The broader literature summarized here also emphasizes that the most effective salt-reduction efforts tend to be multi-component, population-level strategies involving policy, education, and industry reformulation rather than relying solely on individual discretionary control.

Key gaps include the need for more high-quality, long-duration randomized evidence on effectiveness and safety of salt-reduction strategies in high-risk groups (especially older adults and those susceptible to hyperkalemia when using potassium-based substitutes), and comparative effectiveness studies that separate the impacts of sodium reduction versus potassium increase. Implementation research is needed to identify scalable approaches that reduce sodium in processed foods while maintaining food quality, safety, and consumer acceptance—particularly in major sodium contributors such as meat products, where single technologies appear insufficient and combined strategies are proposed. Finally, mechanistic pathways linking salt to immune dysregulation/autoimmunity and to organ-specific injury (kidney/brain/vasculature) require further human validation, including biomarkers and intervention studies that test whether targeting identified pathways yields clinical benefit.

1. What conditions has Salt been studied for?

  • Hypertension (high blood pressure): Multiple abstracts focus on high salt intake as a driver of elevated blood pressure, and on salt-reduction strategies (including potassium-enriched salt substitutes) to lower blood pressure.

  • Cardiovascular disease (CVD) and cardiovascular events: Excess salt intake is linked to cardiovascular morbidity/mortality globally, and one trial tested whether a salt substitute reduces cardiovascular events in older adults.

  • Heart failure and cardiac hypertrophy (pre-heart-failure remodeling): One animal study examined high-salt–induced cardiac hypertrophy and metabolic/mitochondrial mechanisms, and tested pharmacologic mitigation (canagliflozin) under high-salt loading.

  • Autoimmunity / immune dysregulation: One abstract notes high salt may promote autoimmunity by inducing T helper 17 (Th17) responses (mechanistic/immune pathway focus).

  • Kidney-related traditional syndrome (KYDS) in Traditional Chinese Medicine context: “Salt processing” of an herb (Eucommiae Cortex) was studied for enhanced efficacy in KYDS; this is not dietary salt intake per se, but a salt-processing method affecting herbal composition and effects.

  • Food technology / sodium reduction in meat products: Salt’s functional roles in meat processing and strategies to reduce sodium in processed meats were reviewed (public health relevance via dietary exposure).

  • Drug development (pharmaceutical salt forms): Salt forms of active pharmaceutical ingredients were reviewed for effects on drug properties (not a “treatment condition,” but a major biomedical application of “salts”).

  • Metabolic effects in salt-sensitive hypertension models: One metabolomics abstract reports high salt lowers circulating beta-hydroxybutyrate (βOHB) in hypertensive rats, suggesting links to metabolic syndrome biology.

2. Does it work in treating those conditions? Summarize the evidence.

  • Dietary salt reduction / salt substitutes for hypertension:

    • Potassium-enriched salt substitute in older adults (cluster randomized trial, 2 years, China): Salt substitute (62.5% NaCl, 25% KCl) lowered systolic BP by -7.1 mmHg (95% CI -10.5 to -3.8) and diastolic BP by -1.9 mmHg (95% CI -3.6 to -0.2) versus usual salt. It also reduced cardiovascular events (HR 0.60, 95% CI 0.38–0.96), with no significant effect on total mortality (HR 0.84, 95% CI 0.63–1.13).

    • Salt supply restriction in the same trial: Progressively restricted supply (of salt or salt substitute) had no effect on systolic BP or other outcomes in that setting.

    • Meta-analytic evidence summarized in a review: Replacing sodium chloride with potassium-enriched salt substitutes lowered BP on average by about -5.58 mmHg systolic (95% CI -7.08 to -4.09) and -2.88 mmHg diastolic (95% CI -3.93 to -1.83).

    • Limitations noted: One review highlights a “paucity of high-quality evidence” on effectiveness and safety of salt reduction strategies in older people overall, despite the large trial above providing stronger evidence in one population and setting.

  • High salt intake as a cause/risk factor (not a treatment):

    • Across abstracts, high salt intake is consistently framed as harmful—associated with high blood pressure and estimated to contribute to large global mortality (~5 million deaths/year attributed to excess salt intake in one review).

    • Animal/mechanistic work links high salt to organ pathology (kidney/brain/vasculature/immune system) and to cardiac hypertrophy with mitochondrial/metabolic dysfunction.

  • Cardiac hypertrophy under high salt loading (animal evidence; pharmacologic mitigation):

    • In Dahl salt-sensitive rats fed an 8% high-salt diet, canagliflozin improved salt-induced cardiac hypertrophy and mitochondrial function, associated with restoration of SIRT3. Cardiac-specific SIRT3 knockout worsened hypertrophy and abolished canagliflozin’s benefit, supporting a mechanistic role for SIRT3 repression in salt-induced hypertrophy. This suggests potential therapeutic pathways, but it does not show that salt itself “treats” hypertrophy—rather, it models salt as an injurious exposure.

  • KYDS and salt-processed Eucommiae Cortex (preclinical/experimental evidence):

    • Salt processing of Eucommiae Cortex was reported to produce stronger effects than raw herb on hormonal indices (HPA/HPT axis markers) and renal lesions in a KYDS model, with candidate active compounds identified. This evidence pertains to salt-processing of an herb, not dietary salt intake, and generalizability to clinical outcomes is uncertain from the abstract alone.

3. What health benefits does it have?

  • Physiological necessity: One review emphasizes salt intake is a “biological imperative” integrated into physiology (i.e., sodium is essential for fluid balance, nerve conduction, and other core functions). The abstracts do not quantify an “optimal” intake, but they frame harm primarily around excess.

  • Blood pressure and cardiovascular benefit via sodium reduction strategies:

    • Potassium-enriched salt substitutes can lower blood pressure (trial: -7.1 mmHg systolic; review: average ~-5.6 mmHg systolic) and, in one 2-year cluster randomized trial in elderly care facilities, were associated with fewer cardiovascular events (HR 0.60).

  • Food technology benefits (functional roles in processing): In meat products, sodium salt contributes to processing qualities (reviewed in the abstract), which is why reduction is technically challenging and often requires combined strategies to maintain product quality.

  • Pharmaceutical benefits (salt forms of drugs): Choosing appropriate salt forms of active pharmaceutical ingredients can improve drug performance (e.g., pharmacokinetics/pharmacodynamics and overall therapeutic/pharmaceutical effects), whereas an inappropriate salt form can be detrimental.

4. Does it have any downsides or side effects?

  • Excess dietary salt intake (sodium chloride):

    • Higher blood pressure and associated cardiovascular morbidity/mortality: Excess salt intake is associated with high blood pressure and is estimated in one review to contribute to ~5 million deaths per year worldwide.

    • Cardiac remodeling risk: High salt loading in salt-sensitive animal models provokes cardiac hypertrophy and metabolic/mitochondrial dysfunction (mechanistic evidence).

    • Potential immune effects: One abstract notes high salt may promote autoimmunity by inducing Th17 responses (mechanistic; clinical impact not established in these abstracts).

    • “Hidden salt” problem: Processed foods can contain substantial sodium, reducing individuals’ ability to control intake; inequalities in food systems may worsen this barrier (population-health implementation concern).

  • Potassium-enriched salt substitutes (KCl-containing):

    • Hyperkalemia risk: A review notes the principal concern is hyperkalemia (with potential arrhythmias/sudden cardiac death), especially in people with impaired potassium excretion (e.g., chronic kidney disease). It also states evidence is insufficient regarding actual hyperkalemia outcomes at the population level.

    • Trial safety findings: In the 2-year cluster randomized trial, salt substitute increased mean serum potassium and caused more frequent biochemical hyperkalemia, but was not associated with adverse clinical outcomes in that study.

  • Salt restriction strategy limitations: In the elderly care facility trial, restricting salt supply did not improve BP or outcomes, suggesting some “restriction” approaches may be ineffective depending on implementation/adherence/context.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report human pharmacogenomic findings (i.e., specific genetic variants that predict benefit/harm from salt intake, salt reduction, or salt substitutes).

  • Mechanistic genetic evidence (animal model): The cardiac hypertrophy study used SIRT3 cardiac-specific knockout mice to show SIRT3 is necessary for canagliflozin’s protective effect under high-salt loading. This demonstrates a gene-dependent mechanism in an experimental model, but it is not directly translatable to human pharmacogenomic guidance without additional evidence.

  • Salt sensitivity: Several abstracts refer to “salt-sensitive” hypertension/models (e.g., Dahl salt-sensitive rats), implying biological heterogeneity in response to salt. However, no specific human genetic variants are identified in these abstracts.

References

  1. Salt-responsive gut commensal modulates T
    Nicola Wilck, Mariana G Matus, Sean M Kearney, Scott W Olesen, Kristoffer Forslund, Hendrik Bartolomaeus, Stefanie Haase, Anja Mähler, András Balogh, Lajos Markó, Olga Vvedenskaya, Friedrich H Kleiner, Dmitry Tsvetkov, Lars Klug, Paul I Costea, Shinichi Sunagawa, Lisa Maier, Natalia Rakova, Valentin Schatz, Patrick Neubert, Christian Frätzer, Alexander Krannich, Maik Gollasch, Diana A Grohme, Beatriz F Côrte-Real, Roman G Gerlach, Marijana Basic, Athanasios Typas, Chuan Wu, Jens M Titze, Jonathan Jantsch, Michael Boschmann, Ralf Dechend, Markus Kleinewietfeld, Stefan Kempa, Peer Bork, Ralf A Linker, Eric J Alm, Dominik N Müller (2017) - Nature
  2. Effect of sodium salt on meat products and reduction sodium strategies - A review.
    Ji Wang, Xu-Hui Huang, Yu-Ying Zhang, Shengjie Li, Xiuping Dong, Lei Qin (2023) - Meat science
  3. The impact of excessive salt intake on human health.
    Robert W Hunter, Neeraj Dhaun, Matthew A Bailey (2022) - Nature reviews. Nephrology
  4. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial.
    Yifang Yuan, Aoming Jin, Bruce Neal, Xiangxian Feng, Qianku Qiao, Hongxia Wang, Ruijuan Zhang, Jiayu Li, Peifen Duan, La'e Cao, Hui Zhang, Senke Hu, Huijuan Li, Pei Gao, Gaoqiang Xie, Jianhui Yuan, Lili Cheng, Sujuan Wang, Haijun Zhang, Wenyi Niu, Hai Fang, Minghui Zhao, Runlin Gao, Junshi Chen, Paul Elliott, Darwin Labarthe, Yangfeng Wu (2023) - Nature medicine
  5. Study on the substance basis of the efficacy of eucommiae cortex before and after salt processing for the treatment of kidney-yang deficiency syndrome based on the spectrum-effect relationship.
    Hangsha Wu, Yue Lv, Mingfang Zhao, Rui Tang, Yafei Li, Keer Fang, Feiyang Wei, Weihong Ge, Weifeng Du, Changyu Li, Yefeng Zhang (2024) - Journal of ethnopharmacology
  6. Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression.
    Yu Zhao, Zongshi Lu, Hexuan Zhang, Lijuan Wang, Fang Sun, Qiang Li, Tingbing Cao, Bowen Wang, Huan Ma, Mei You, Qing Zhou, Xiao Wei, Li Li, Yingying Liao, Zhencheng Yan, Daoyan Liu, Peng Gao, Zhiming Zhu (2025) - Journal of advanced research
  7. Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations.
    Deepak Gupta, Deepak Bhatia, Vivek Dave, Vijaykumar Sutariya, Sheeba Varghese Gupta (2018) - Molecules (Basel, Switzerland)
  8. Potassium-Enriched Salt Substitutes as a Means to Lower Blood Pressure: Benefits and Risks.
    Raquel C Greer, Matti Marklund, Cheryl A M Anderson, Laura K Cobb, Arlene T Dalcin, Megan Henry, Lawrence J Appel (2020) - Hypertension (Dallas, Tex. : 1979)
  9. New insights into microbial bile salt hydrolases: from physiological roles to potential applications.
    Zixing Dong, Shuangshuang Yang, Cunduo Tang, Dandan Li, Yunchao Kan, Lunguang Yao (2025) - Frontiers in microbiology
  10. Phytates as a natural source for health promotion: A critical evaluation of clinical trials.
    Sónia M G Pires, Rita Silva Reis, Susana M Cardoso, Raffaele Pezzani, Esteban Paredes-Osses, Ainur Seilkhan, Alibek Ydyrys, Miquel Martorell, Eda Sönmez Gürer, William N Setzer, Ahmad Faizal Abdull Razis, Babagana Modu, Daniela Calina, Javad Sharifi-Rad (2023) - Frontiers in chemistry
  11. Salt-Responsive Metabolite, β-Hydroxybutyrate, Attenuates Hypertension.
    Saroj Chakraborty, Sarah Galla, Xi Cheng, Ji-Youn Yeo, Blair Mell, Vishal Singh, BengSan Yeoh, Piu Saha, Anna V Mathew, Matam Vijay-Kumar, Bina Joe (2018) - Cell reports
  12. Bile Salt Hydrolases: At the Crossroads of Microbiota and Human Health.
    Mélanie Bourgin, Aicha Kriaa, Héla Mkaouar, Vincent Mariaule, Amin Jablaoui, Emmanuelle Maguin, Moez Rhimi (2021) - Microorganisms
  13. Dietary factors that affect the risk of pre-eclampsia.
    Abigail Perry, Anna Stephanou, Margaret P Rayman (2022) - BMJ nutrition, prevention & health
  14. The remarkable impact of iodisation programmes on global public health.
    Michael B Zimmermann (2023) - The Proceedings of the Nutrition Society
  15. The role of taurine in male reproduction: Physiology, pathology and toxicology.
    Yuanyuan Li, Qianwen Peng, Jia Shang, Wanglin Dong, Sijia Wu, Xiajun Guo, Zhenxing Xie, Chaoran Chen (2023) - Frontiers in endocrinology
  16. The role of dietary salt in metabolism and energy balance: Insights beyond cardiovascular disease.
    Qi Wu, George Burley, Li-Cheng Li, Shu Lin, Yan-Chuan Shi (2023) - Diabetes, obesity & metabolism
  17. Taxes and Subsidies for Improving Diet and Population Health in Australia: A Cost-Effectiveness Modelling Study.
    Linda J Cobiac, King Tam, Lennert Veerman, Tony Blakely (2017) - PLoS medicine
  18. Strategies to Reduce Salt Content and Its Effect on Food Characteristics and Acceptance: A Review.
    Siti Nurmilah, Yana Cahyana, Gemilang Lara Utama, Abderrahmane Aït-Kaddour (2022) - Foods (Basel, Switzerland)
  19. Assessment of Yeasts as Potential Probiotics: A Review of Gastrointestinal Tract Conditions and Investigation Methods.
    Nadia S Alkalbani, Tareq M Osaili, Anas A Al-Nabulsi, Amin N Olaimat, Shao-Quan Liu, Nagendra P Shah, Vasso Apostolopoulos, Mutamed M Ayyash (2022) - Journal of fungi (Basel, Switzerland)
  20. Bacteriocin production: a relatively unharnessed probiotic trait?
    James W Hegarty, Caitriona M Guinane, R Paul Ross, Colin Hill, Paul D Cotter (2016) - F1000Research


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!